Department of Biomedicine, University Hospital Basel, Basel, CH-4031, Switzerland.
Diabetol Metab Syndr. 2011 Jul 20;3:16. doi: 10.1186/1758-5996-3-16.
Adipokines, e.g. TNFα, IL-6 and leptin increase insulin resistance, and consequent hyperinsulinaemia influences breast cancer progression. Beside its mitogenic effects, insulin may influence adipokine production from adipocyte stromal cells and paracrine enhancement of breast cancer cell growth. In contrast, adiponectin, another adipokine is protective against breast cancer cell proliferation and insulin resistance.AMP-activated protein kinase (AMPK) activity has been found decreased in visceral adipose tissue of insulin-resistant patients. Lipopolysaccharides (LPS) link systemic inflammation to high fat diet-induced insulin resistance. Modulation of LPS-induced adipokine production by metformin and AMPK activation might represent an alternative way to treat both, insulin resistance and breast cancer.
Human preadipocytes obtained from surgical biopsies were expanded and differentiated in vitro into adipocytes, and incubated with siRNA targeting AMPKalpha1 (72 h), LPS (24 h, 100 μg/ml) and/or metformin (24 h, 1 mM) followed by mRNA extraction and analyses. Additionally, the supernatant of preadipocytes or derived-adipocytes in culture for 24 h was used as conditioned media to evaluate MCF-7 breast cancer cell proliferation.
Conditioned media from preadipocyte-derived adipocytes, but not from undifferentiated preadipocytes, increased MCF-7 cell proliferation (p < 0.01). Induction of IL-6 mRNA by LPS was reduced by metformin (p < 0.01), while the LPS-induced mRNA expression of the naturally occurring anti-inflammatory cytokine interleukin 1 receptor antagonist was increased (p < 0.01). Silencing of AMPKalpha1 enhanced LPS-induced IL-6 and IL-8 mRNA expression (p < 0.05).
Adipocyte-secreted factors enhance breast cancer cell proliferation, while AMPK and metformin improve the LPS-induced adipokine imbalance. Possibly, AMPK activation may provide a new way not only to improve the obesity-related adipokine profile and insulin resistance, but also to prevent obesity-related breast cancer development and progression.
脂肪因子,如 TNFα、IL-6 和瘦素,会增加胰岛素抵抗,随之而来的高胰岛素血症会影响乳腺癌的进展。除了有丝分裂作用外,胰岛素还可能影响脂肪细胞基质细胞的脂肪因子产生和乳腺癌细胞生长的旁分泌增强。相比之下,另一种脂肪因子脂联素可以防止乳腺癌细胞增殖和胰岛素抵抗。
已发现,胰岛素抵抗患者内脏脂肪组织中的 AMP 激活蛋白激酶 (AMPK) 活性降低。脂多糖 (LPS) 将全身炎症与高脂肪饮食诱导的胰岛素抵抗联系起来。二甲双胍和 AMPK 激活对 LPS 诱导的脂肪因子产生的调节可能代表治疗胰岛素抵抗和乳腺癌的另一种方法。
从手术活检中获得的人前脂肪细胞在体外扩增并分化为脂肪细胞,并与针对 AMPKalpha1 的 siRNA(72 小时)、LPS(24 小时,100μg/ml)和/或二甲双胍(24 小时,1mM)孵育,然后提取 mRNA 并进行分析。此外,培养 24 小时的前脂肪细胞或衍生的脂肪细胞的上清液用作条件培养基,以评估 MCF-7 乳腺癌细胞的增殖。
前脂肪细胞衍生的脂肪细胞的条件培养基,但不是未分化的前脂肪细胞的条件培养基,增加了 MCF-7 细胞的增殖(p <0.01)。二甲双胍降低了 LPS 诱导的 IL-6 mRNA 的产生(p <0.01),而 LPS 诱导的天然抗炎细胞因子白细胞介素 1 受体拮抗剂的 mRNA 表达增加(p <0.01)。AMPKalpha1 的沉默增强了 LPS 诱导的 IL-6 和 IL-8 mRNA 的表达(p <0.05)。
脂肪细胞分泌的因子增强了乳腺癌细胞的增殖,而 AMPK 和二甲双胍改善了 LPS 诱导的脂肪因子失衡。可能,AMPK 激活不仅为改善肥胖相关脂肪因子谱和胰岛素抵抗提供了一种新方法,而且为预防肥胖相关乳腺癌的发生和发展提供了一种新方法。